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CytokinesRose-oxide is a fragrance found in roses and rose oil. There are no reports about the pharmacological activity of
this molecule. The present study was undertaken to evaluate whether rose-oxide (RO) has anti-inﬂammatory
properties and to investigate possible mechanisms involved with its effects. The anti-inﬂammatory activity
of RO was ﬁrst suggested by the formalin test in mice, an inﬂammatory pain model, because intraperitoneal
(i.p.) administration of RO (50 and 100 mg/kg) inhibited only the late phase of this test. To further investigate
the anti-inﬂammatory properties of RO, the complete Freund's adjuvant (CFA)- and carrageenan-induced paw
inﬂammation models were used. Pre-treatment with RO (50 and 100 mg/kg) signiﬁcantly reduced paw
edema at 4, 6 and 24 h after the CFA injection. In addition, RO (100 mg/kg) reduced the IL-1β, but not
TNF-α, local production induced by CFA. Administration of RO (25–100 mg/kg) decreased the paw edema
induced by carrageenan in rats, which was more evident at 3 and 4 h after induction. In addition, neutrophil
migration to the hind pawwas measured by MPO assay after the carrageenan injection. The MPO activity was
signiﬁcantly inhibited by RO at 25–100 mg/kg, 4 h after stimulus. In another experimental set, administration
of RO (25–100 mg/kg) signiﬁcantly reduced the leukocyte migration in the carrageenan-induced peritonitis
model in mice. The results described here are the ﬁrst report of pharmacological properties of RO and strongly
suggest that RO possesses anti-inﬂammatory activity related to its ability to inhibit the IL-1β production and
the leukocyte migration.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Inﬂammation is derived from the Latin word inﬂammatio, which
means to set alight. It is part of the complex biological response of vas-
cular tissues to harmful stimuli, such as pathogens, damaged cells, or
irritants. Thus, inﬂammation is a protective attempt by the organism
to remove the injurious stimuli and to initiate the healing process.
On the other hand, the outcomemay be deleterious if it leads to chron-
ic inﬂammation without resolution of the underlying injurious pro-
cess. The clinical treatment of inﬂammatory diseases is dependent
on non-steroidal or steroidal chemical therapeutics [1]. Nonsteroidal
antiinﬂammatory drugs (NSAID) reduce the pain and inﬂammation
by blocking the metabolism of arachidonic acid by cyclooxygenase
enzyme (COX), and thereby the production of prostaglandin [2].
Since prostaglandins are cytoprotective, long term administration ofTecidual e Imunofarmacologia,
o Cruz, Waldemar Falcão 121
5 71 31762260; fax: +55 71
vier OA license.NSAID may induce gastro-intestinal ulcers, bleeding, and renal disor-
ders due to their non-selective inhibition of both isoforms of the
COX enzyme, the constitutive (COX-1) and the inducible (COX-2)
isoforms [3]. On the other hand, fully selective and reversible COX-2
inhibitors with reduced gastro-intestinal toxicity have been asso-
ciated with adverse cardiovascular effects [4]. Furthermore, the use
of steroidal drugs as antiinﬂammatory agents is also becoming highly
controversial due to their multiple side effects [5,6].
There is currently strong interest in the development of new
anti-inﬂammatory agents, with potentially less side effects, based
on natural products. Rose-oxide is an organic compound of the mono-
terpene class and a fragrance found in roses and rose oil such as the
Bulgarian rose, Geranium, Damask rose, Laggera spp., Eucalyptus
citriodora, and Dracocephalum heterophyllum [7–9]. Rose-oxide also
contributes to the ﬂavor of some fruits such as lychee and can be in-
dustrially produced based on the photooxygenation of citronellol
[10]. Due to its commercial application, many studies evaluating the
use of rose-oxide in the production of ﬂavorings have been reported.
However, as the time of writing, there are currently no reports about
its pharmacological activities. The present study was undertaken to
evaluate whether rose-oxide (RO) has anti-inﬂammatory properties
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To the best of our knowledge, this is the ﬁrst report of pharmaco-
logical properties of rose-oxide.
2. Material and methods
2.1. Animals
Experimentswere performed onmale SwissWebstermice (22–28 g)
obtained from the Animal Facilities of Centro de Pesquisas Gonçalo
Moniz or male Wistar rats (150–200 g) obtained from the Animal
House of the Federal University of Sergipe. Animals were housed in
temperature-controlled rooms (22–25 °C), under a 12:12 h light–dark
cycle, with access to water and food ad libitum until use. All behavioral
tests were performed between 8:00 a.m. and 5:00 p.m., and animals
were only used once. Animal care and handling procedures were in
accordance with the Institutional Animal Care and Use Committee of
the Gonçalo Moniz Research Center (FIOCRUZ L-029/2009). Every effort
was made to minimize the number of animals used and any discomfort.
Behavioral tests were done without knowing to which experimental
group each mouse belonged. Results shown are from two independent
experiments performed.
2.2. Formalin test
Mice were placed in an open Plexiglas observation chamber for
30 min to accommodate to their surroundings, and then removed
for formalin administration. Mice were gently restrained while the
hind paw received an intraplantar administration of 20 μL of 2.5% for-
malin (1:100 dilution of stock formalin solution, 37% formaldehyde in
0.9% saline), using a 30 gauge needle. Following injection, mice were
returned to the observation chamber for a 30 min observation period.
Mice were observed from 0 to 10 min (early phase) and from 10 to
30 min (late phase), and a nociception score was determined for
each period by counting the time that the animal spent licking the
injected paw during the observation time [11]. Mice were treated
with RO (25–100 mg/kg), vehicle (Tween 20, 5% in saline; control
group), or indomethacin (10 mg/kg; reference drug), by intraperito-
neal (i.p.) route 30 min before formalin.
2.3. Paw inﬂammation induced by complete Freund's adjuvant
Mice were slightly anesthetized with halothane and received
20 μL of complete Freund's adjuvant (CFA; 1 mg/mL of heat killed
Mycobacterium tuberculosis in 85% parafﬁn oil and 15% mannide
monoleate) in the right hind paw, according to a method previously
reported [12]. Mice were injected with RO (25–100 mg/kg) or vehicle
(Tween 20, 5% in saline; control group) by the i.p. route 30 min be-
fore CFA. Dexamethasone (2 mg/kg), the reference drug, was admin-
istered by subcutaneous route (s.c.) 4 h before stimulus. Paw edema
and local levels of cytokines were measured by plesthismometer
and ELISA, respectively, as described below.
2.4. Paw edema test
The volume of each mouse paw was measured with a
plesthismometer (Ugo Basile, Comerio, Italy) before (Vo) the i.p.
injection of CFA and 2, 4, 6 and 24 h after the CFA stimulus (VT), as
described previously [13]. The amount of paw swelling was deter-
mined for each mouse and the difference between VT and Vo was
taken as the edema value (mm3/paw).
2.5. Cytokine measurements
Skin tissues were removed from the paws 2 h after the i.pl. injec-
tion of CFA, in mice terminally anesthetized with isoﬂurane andposterior cervical dislocation from each experimental group. Tissue
proteins were extracted from 100 mg of tissue/mL of PBS to which
0.4 M NaCl, 0.05% Tween 20 and protease inhibitors (0.1 mM PMSF,
0.1 mM benzethonium chloride, 10 mM EDTA, and 20 KI aprotinin
A/100 mL) were added. The samples were centrifuged for 10 min at
3000 g and the supernatant was frozen at−70 °C for later quantiﬁca-
tion [14]. Interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α)
levels were estimated using commercially available immunoassay
ELISA kits for mice (R&D System, Minneapolis, MN), according to
the manufacturer's instructions. The results are expressed as pico-
grams of cytokine per mL of protein solution. As controls, the concen-
trations of these cytokines were determined in vehicle-treated mice
and dexamethasone (positive control).
2.6. Paw inﬂammation induced by carrageenan
Rats were anesthetized with inhaled isoﬂurane and received an
intraplantar injection of carrageenan 1% or sterile saline in the right
paw in a ﬁnal volume of 100 μL. RO (25–100 mg/kg) or vehicle
(Tween 20, 5% in saline; control group) was administered by the i.p.
route 30 min before carrageenan. Dexamethasone (2 mg/kg) was
administered by s.c. route 1 h before stimulus. The paw volume was
assessed by plesthismometer, as described above. The area under
curve (AUC0—4 h) was also calculated using the trapezoidal rule. In
another set of experiments, the myeloperoxidase (MPO) activity in
rat paw was measured. Skin tissues were removed from the paws
4 h after the injection of carrageenan in rats terminally anesthetized
with isoﬂurane and posterior cervical dislocation. The tissue was
immediately collected and placed in a test tube in the presence of
0.5% of hexadecyltrimethylammonium bromide in 50 mmol/L potas-
sium phosphate buffer (pH 6.0). Each tissue sample was homoge-
nized and the homogenate was centrifuged at 12,000 g for 5 min.
The supernatants were collected and the MPO assay was performed
using a microliter plate scanner, according to Bradley et al. [15]
with minor modiﬁcations. This consisted of mixing 10 μL of sample
with 200 μL of o-dianisidine solution (0.167 mg/mL of o-dianisidine
dihydrochoride and 0.0005% hydrogen peroxide) before reading the
plate. The changes in absorbance were measured at 460 nm for 15 s
over a period of 5 min. The MPO activity was expressed as MPO
units (U MPO) per milligram of tissue. One unit of MPO activity was
deﬁned as that degrading 1 μmol of peroxide per minute at 25 °C
[16].
2.7. Leukocyte migration to peritoneal cavity
Mice were pretreated with RO (25–100 mg/kg) or vehicle (Tween
20, 5% in saline; control group) by the i.p. route 30 min before the i.p.
injection of carrageenan (1%; 250 μL). Four hours after, the mice were
euthanized under isoﬂurane anesthesia and 2 mL of a phosphate-
buffered saline (PBS, pH 7.4) containing heparin (5 UI/mL) solution
was injected into the peritoneal cavity. The abdomen was carefully
massaged and the ﬂuid was withdrawn, placed in polypropylene
centrifuge tubes and centrifuged at 1000 g for 10 min. The resulting
cell pellet was gently resuspended in 1.0 mL of PBS–heparin solution
and the total and differential cell counts were assayed. Total cell
counts were done using a Neubauer chamber while differential
counts were carried out on a minimum of 200 cells using a cytospin
preparation stained with Diff-Quick. The cells were classiﬁed as
polymorphonuclear (neutrophils and eosinophils) or mononuclear
(macrophages, mast cells and lymphocytes) based on normal mor-
phological criteria.
2.8. Exudate macrophages
Peritoneal exudate cells were obtained by washing with cold
Hank's balanced salt solution (HBSS; Life Technologies, GIBCO-BRL,
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of 3% thioglycollate (Sigma-Aldrich, St. Louis, MO, USA) in saline
(3.0 mL per mouse). Mice were treated with RO (50 and 100 mg/kg)
or vehicle (Tween 20, 5% in saline; control group) by i.p. route
30 min before peritoneal lavage. Peritoneal exudate cells were plated
in 24-well plates at 1×106 cells/well, in RPMI medium supplemented
with 10% FCS. After 2 h of incubation at 37 °C, nonadherent cells were
removed by washing with complete RPMI. Cultures were then stimu-
lated with 500 ng/mL lipopolysaccharide (from Escherichia coli sero-
type 0111:B4, Sigma). Cell-free supernatants were collected at 6 h
for determination of IL-1β concentration by ELISA.
2.9. Drugs
(+)-Rose oxide (RO) was purchased from Fluka (Steinheim,
Germany), with 99.0% of purity. Among the known isomers, the
isomer (+)-rose oxide is the least studied on biological activities,
therefore, this compound was selected for pharmacological evalua-
tion [17,18]. Indomethacin, dexamethasone, carrageenan, complete
Freund's adjuvant (CFA), phosphate buffered saline (PBS), Tween
20, phenylmethylsulphonyl ﬂuoride (PMSF), benzamethonium chlo-
ride, EDTA, aproptinin A and 3,3′,5,5′-tetramethylbenzidine (TMB),
were obtained from Sigma Chemical Company (St. Louis, MO, USA).
Indomethacin was dissolved in Tris HCl 0.1 M pH 8.0 plus saline.
Dexamethasone (1 mg/mL) was dissolved in ethanol (10% in normal
saline). Remaining drugs were dissolved directly in saline.
2.10. Data analysis
Data are presented as means±SEM of measurements made on
6–9 animals in each group. Comparisons across three or more treat-
ments were made using one-way ANOVA with Tukey's post hoc test
or repeated measures two-way ANOVA with Bonferroni's post hoc
test, when appropriate. All data were analyzed using the Prism 5.01
computer software (GraphPad, San Diego, USA). Statistical differences
were considered to be signiﬁcant at pb0.05.
3. Results
The anti-inﬂammatory properties of RO were evaluated initially
using the formalin test in mice, an inﬂammatory pain model. The
injection of formalin in control animals induced a biphasic licking re-
sponse, with the early phase ranging from 0 to 10 min (Fig. 1a) and
the late phase from 10 to 30 min (Fig. 1b) after the injection. Treatment
with RO (50 and 100 mg/kg, i.p.) or indomethacin (10 mg/kg, i.p.),
30 min before the formalin, inhibited only the late phase of the formalin
test (pb0.05). Next, the effects of treatment with RO were assessed
in the complete Freund's adjuvant (CFA)-induced paw inﬂammationFig. 1. Effects of the rose-oxide (RO) treatment on inﬂammatory pain induced by form
formalin-induced nociception in mice, respectively. Mice were treated with RO (25, 50 a
30 min before formalin (injected at time zero). Indomethacin (In; 10 mg/kg, i.p.) was the p
different from the control group (pb0.05) as determined by ANOVA followed by Tukey's temodel. Paw edema and local levels of inﬂammatory cytokines were
evaluated throughout the experimental period. The administration of
RO (50 and 100 mg/kg, i.p.) 30 min before CFA reduced signiﬁcantly
(pb0.01) the paw edema at 4, 6, and 24 h after the CFA injection
(Fig. 2). The results obtained with control groups supported the effects
of RO, since the vehicle (Tween 20, 5% in saline) had no activity, and the
paw edema was strongly inhibited by dexamethasone (2 mg/kg, s.c.).
In addition, the pre-treatment with RO (100 mg/kg) reduced the
IL-1β, but not TNF-α, local production induced by CFA (Fig. 3). Dexa-
methasone (2 mg/kg, s.c.), the reference drug, reduced both the IL-1β
and the TNF-α concentrations on inﬂamed paws.
Next, a possible direct action of RO on inﬂammatory cells was
evaluated using exudate macrophages obtained by a peritoneal
lavage of RO-treated animals. Upon stimulation with lipopolysac-
charide, macrophage cultures from RO (100 mg/kg)-treated mice
produced signiﬁcantly less IL-1β than macrophages obtained from
vehicle-treated animals (pb0.05; Fig. 4).
Aiming to further evaluate the anti-inﬂammatory properties of RO
the carrageenan-induced paw inﬂammation model was also used.
The intraplantar injection of carrageenan increased the rat paw vol-
ume with maximal effect 3 h after stimuli. Pretreatment of rats with
RO (25–100 mg/kg, i.p.) decreased the paw edema induced by carra-
geenan (Fig. 5a), which was more evident 3 and 4 h after induction.
Rats pretreated with dexamethasone (2 mg/kg) also had a signiﬁcant
reduction of edema. The AUC0–4 h analysis of the relationship be-
tween paw volume (mm3/paw)×time (h) clearly showed the anti-
edematogenic action of RO. Pretreatment with RO at 25, 50 or
100 mg/kg signiﬁcantly reduced the AUC0–4 h (2.6±0.3, pb0.05;
2.4±0.4, pb0.01 or 2.2±0.2, pb0.01, respectively) when compared
with the vehicle-treated group (3.8±0.2), an effect also observed
when dexamethasone was given as pre-treatment (1.3±0.1,
pb0.001). In addition to the paw edema, neutrophil migration to the
hind paw was measured by MPO assay after the carrageenan injection.
A high activity of MPO in the hind paw plantar tissues was detected
after the carrageenan injection (Fig. 5b). The carrageenan-induced
MPO activity was signiﬁcantly inhibited by RO at 25 (pb0.05), 50
(pb0.001) or 100 mg/kg (pb0.01). The MPO activity was also de-
creased by dexamethasone treatment (pb0.01).
In another set of experiments, the effects of the treatment with RO
were investigated in a carrageenan-induced peritonitis model in mice
(Table 1). The intraperitoneal injection of carrageenan induced a
marked leukocyte migration, characterized mainly by neutrophils, in
the peritoneal cavity of mice. Eosinophils were virtually absent in all
groups analyzed. The previous administration of RO signiﬁcantly
reduced the total leukocyte number at 25 (pb0.05), 50 (pb0.01) or
100 mg/kg (pb0.001). This was also observed for polymorphonuclear
(neutrophil) cell counts at all doses used. Mice treated with dexa-
methasone (2 mg/kg) also showed a signiﬁcant decrease in the totalalin. Panels (A) and (B) represent effects of RO on the early and late phases of
nd 100 mg/kg) or vehicle (Tween 20, 5% in saline; control group) by the i.p. route
ositive control. Data are expressed as means±SEM of 6 mice per group. *Signiﬁcantly
st.
Fig. 2. Effects of the rose-oxide (RO) treatment on complete Freund's adjuvant
(CFA)-induced paw inﬂammation measured at 2, 4, 6 and 24 h after the CFA stimulus.
Mice were injected with RO (25, 50 and 100 mg/kg) and vehicle (Tween 20, 5% in
saline; control group) by the i.p. route 30 min before CFA and dexamethasone (2 mg/kg;
positive control) by the subcutaneous route 4 h before CFA (injected at time zero). Data
are expressed asmeans±SEMof 6mice per group. *Signiﬁcantly different from the control
group (pb0.01). Two-way ANOVA followed by the Bonferroni's test.
Fig. 4. Reduction of interleukin-1β (IL-1β) production by macrophages from rose-oxide
treated mice. Mice were treated with rose-oxide (RO; 50 and 100 mg/kg) or vehicle
(Tween 20, 5% in saline; control group) by the i.p. route 30 min before peritoneal lavage.
Peritoneal exudate macrophages from treated mice were stimulated in vitro with lipo-
polysaccharide. Cell-free supernatants were collected after 6 h and tested for production
of IL-1β by ELISA. Data are expressed as means±SEM of 6 experiments. *Signiﬁcantly
different from the control group (pb0.001) as determined by ANOVA followed by Tukey's
test.
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not affected by pretreatment with RO at 25 or 50 mg/kg or dexameth-
asone, but were signiﬁcantly reduced by RO at 100 mg/kg (pb0.05).4. Discussion
The present study has demonstrated, for the ﬁrst time, the
anti-inﬂammatory properties of rose-oxide. The systemic administra-
tion of rose-oxide inhibited key events related to inﬂammation,
namely edema, local increase of IL-1β level, and leukocyte migration,
producing consistent anti-inﬂammatory effects in different models of
inﬂammation in mice and rats.
Because pain is one of the classic signs of the inﬂammatory process,
the properties of RO were evaluated initially using the formalin test in
mice, a screening tool for the assessment of new antinociceptive and
anti-inﬂammatory substances [11]. This model has two distinct phases
that may indicate different types of pain: the early phase (named
nociceptive), which results essentially from the direct stimulation of
nociceptors, and the late phase (named inﬂammatory pain), caused
by local inﬂammation with a release of inﬂammatory mediators [19].
Treatment with RO caused antinociceptive effects only in the late
phase of the formalin test, a proﬁle similar to that of nonsteroidal
anti-inﬂammatory drugs, which seem to suppress only the second
phase of formalin test, and is in contrast with the proﬁle of central anal-
gesics, which seem to be antinociceptive for both phases [19,20]. This
was a ﬁrst indication of an anti-inﬂammatory action by RO.Fig. 3. Effects of the rose-oxide (RO) on inﬂammatory cytokines on complete Freund's adjuva
ulus. (A) Paw interleukin 1β (IL-1β) levels. (B) Paw tumor necrosis factor α (TNF-α) levels.
group) by the i.p. route 30 min before CFA and dexamethasone (2 mg/kg; positive control) b
means±SEM of 6 mice per group. *Signiﬁcantly different from the control group (pb0.05)To conﬁrm this hypothesis, the effects of RO treatment were
assessed in the complete Freund's adjuvant (CFA)-induced paw
inﬂammation model. It is now well recognized that the inﬂammation
caused by intraplantar injection of CFA involves the release of multi-
ple inﬂammatory mediators, such as cytokines and prostanoids,
which increase blood supply and accumulation of leukocytes,
resulting in local swelling and edema [21,22]. In the present study,
the administration of RO resulted in a marked inhibition of two im-
portant events, the edema and increase in tissue IL-1β levels, which
are related to the inﬂammatory response induced by CFA. Nowadays,
it is well accepted that cytokines constitute a link between cellular
injuries or immunological recognition and the local or systemic
signs of inﬂammation, e.g. cell migration, edema, fever, and hyper-
algesia [23–25]. Different cell types, including macrophages, mono-
cytes, and glial cells produce IL-1β which, in turn, induce the
production of other inﬂammatory mediators involved with cellular
recruitment, such as IL-6, IL-8, adhesion molecules, chemokines,
nitric oxide synthase, and COX-2, fever, acute phase protein release,
and increase of vascular permeability [23,26–29]. Considering the im-
portant role of IL-1β during the inﬂammatory response, we suggest
that the anti-inﬂammatory effects of RO may be related to its ability
to inhibit the release of IL-1β. In addition, in the present study, a
single administration of RO produced an anti-edematogenic effect
that lasted 24 h after its administration. This long-lasting anti-
inﬂammatory effect may reﬂect an interference with the de novo
synthesis of inﬂammatory proteins, reinforcing the idea that thent (CFA)-induced paw inﬂammation. Cytokine levels were measured 3 h after the stim-
Mice were injected with RO at 100 mg/kg and vehicle (Tween 20, 5% in saline; control
y the subcutaneous route 4 h before CFA (injected at time zero). Data are expressed as
as determined by ANOVA followed by Tukey's test.
Fig. 5. Rose oxide (RO) reduced carrageenan (CAR)-induced rat paw edema and neu-
trophil inﬁltration. Panel (a) shows the time course of rat paw edema in animals treat-
ed with vehicle, RO (25–100 mg/kg) or dexamethasone (Dexa, 2 mg/kg) and injected
with carrageenan (CAR 1%) after 40 min. Panel (b) shows the myeloperoxidase (MPO)
activity determined in the rat paws after the 4th hour. Data are expressed as means±
SEM of 6 mice per group. *Signiﬁcantly different from the carrageenan+vehicle group
(pb0.05) as determined by ANOVA followed by the Tukey's test.
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cytokine production. The inhibitory effect of RO on IL-1β production
was next conﬁrmed in vitro, in macrophage cultures. Peritoneal exu-
date macrophages obtained from mice previously treated with RO
produced signiﬁcantly less IL-1β when stimulated with lipopolysac-
charide than macrophages from vehicle-treated animals. This ability
of RO to suppress the stimulated release of IL-1β indicates a direct
action of RO on inﬂammatory macrophages.Table 1
Total and differential leukocyte counts in the peritoneal cavity of mice pretreated with
vehicle, rose oxide (RO) or dexamethasone in the peritonitis model induced by
carrageenan.
Group Cells×106/peritoneal cavity
Total leukocyte Mononuclear Polymorphonuclear
Vehicle 15.4±0.7 4.1±0.4 11.2±0.6
RO (25 mg/kg) 10.6±0.9a 3.6±0.3 7.0±0.7b
RO (50 mg/kg) 9.4±1.3b 3.7±0.4 5.7±1.0c
RO (100 mg/kg) 5.4±0.8c 2.0±0.2a 3.4±0.6c
Dexamethasone (2 mg/kg) 6.1±1.5c 3.0±0.8 3.1±0.8c
Results are presented as mean±S.E.M. of cells×106/peritoneal cavity for n=5 mice.
aPb0.05, bPb0.01 and cPb0.001 compared to carrageenan+vehicle.Conﬁrming the anti-inﬂammatory activity of RO, the edema in-
duced by carrageenan in rats was inhibited to a signiﬁcant extent by
this compound. This result suggests that RO affect the vascular per-
meability, leading to decreased leakage in rat paws. The intraplantar
injection of carrageenan in rodents induces edema associated with
the production of inﬂammatory mediators and leukocyte migration
[30–34]. Thus, the potential usefulness of RO was tested as a pharma-
cological tool to inhibit neutrophil migration induced by inﬂam-
mation. MPO activity is widely used in experimental studies as a
marker of the neutrophil content in various tissues, such as skin
[35], paw [16], and pancreas [36], among others. We found that the
administration of RO decreased the MPO activity, indicating that RO
inﬂuences the paw neutrophil migration induced by carrageenan.
This inhibitory effect of RO on leukocyte migration was further inves-
tigated in the peritonitis model induced by carrageenan in mice,
which is well described as a ﬂogistic agent that increases the total
leukocyte counts in peritoneal cavity, mainly due to a neutrophil
inﬂux [37,38]. In agreement with our previous results, we observed
a marked reduction of carrageenan-induced neutrophil recruitment
to the peritoneal cavity in mice pretreated with RO. This result may
also be associated with the ability of RO to reduce the IL-1β levels,
since it is known that IL-lβ is a potent inducer of leukocyte inﬁltra-
tion into the tissues during the acute phase of an inﬂammatory
reaction [39–41]. A recent report has suggested a role of emigrating
neutrophils in the production and/or release of PGE2 during inﬂam-
mation [42]. Considering that this prostanoid may be crucial for
edema formation [43], the reduction of neutrophil inﬁltration may
also contribute to the anti-edematogenic effect of RO.
The results presented herein strongly suggest that rose-oxide pos-
sesses anti-inﬂammatory activity related to its ability to inhibit the
IL-1β production and the leukocyte migration. However, the precise
mechanisms through which RO exerts its action are currently under
investigation. These results highlight the need for further investiga-
tions of the possible use of RO as a prototype compound for the devel-
opment of new drugs to treat inﬂammatory conditions.References
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